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Abstract 
Background: The initial presentation of acute encephalopathy with biphasic seizures and late 
reduced diffusion (AESD) is indistinguishable from that of complex febrile seizures (FS), 
which poses a great diagnostic challenge for clinicians. Excitotoxicity is speculated to be the 
pathogenesis of AESD. Vitamin B6 (VB6) is essential for the biosynthesis of gamma-
aminobutyric acid, an inhibitory neurotransmitter. The aim of this study is to investigate our 
hypothesis that VB6 deficiency in the brain may play a role in AESD. 
Methods: We obtained cerebrospinal fluid (CSF) samples from pediatric patients with AESD 
after early seizures and those with FS. We measured pyridoxal 5′-phosphate (PLP) and 
pyridoxal (PL) concentrations in the CSF samples using high-performance liquid 
chromatography with fluorescence detection. 
Results: The subjects were 5 patients with AESD and 17 patients with FS. Age did not differ 
significantly between AESD and FS. In AESD, CSF PLP concentration was marginally lower 
(p = 0.0999) and the PLP-to-PL ratio was significantly (p = 0.0417) reduced compared to 
those in FS. 
Conclusions: Although it is impossible to conclude that low PLP concentration and PLP-to-
PL ratio are causative of AESD, this may be a risk factor for developing AESD. When 
combined with other markers, this finding may be useful in distinguishing AESD from FS 
upon initial presentation. 
 
Keywords: AESD, biomarker, febrile seizure, pyridoxal 5′-phosphate, pyridoxal kinase, risk 
factor 
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1. Introduction 
Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a clinically 
and radiographically defined syndrome characterized by epileptic seizures (often status 
epilepticus) at the onset of febrile illness (early seizures), followed by transient recovery of 
consciousness, and subsequent seizure clustering and global cognitive regression 3 to 7 days 
later (late seizures). At this late stage, brain magnetic resonance imaging (MRI) often 
demonstrates restricted diffusion in the subcortical white matter [1]. AESD affects 100 to 200 
children in Japan every year and poses a great challenge for clinicians, because its initial 
manifestation is indistinguishable from that of complex febrile seizure (FS). Research on 
inflammatory markers, neuronal/glial markers, and susceptibility genetic variants has been 
conducted to understand the pathogenesis of AESD [2-5]. At present, however, there remains 
no certain way to distinguish AESD from FS at onset and to prevent late seizures, even if 
AESD is suspected. 
 
Currently there are no established treatments for AESD. There is no evidence that high-dose 
methylprednisolone, intravenous immunoglobulin, or hypo/normothermia therapy are 
efficacious. To improve the neurodevelopmental outcome of AESD, the discovery of reliable 
methods to identify AESD in the early stage and the development of new therapeutic 
strategies based on the pathogenesis of AESD are required. Imbalance between the excitatory 
and inhibitory systems may play a role in AESD. Excitotoxicity has been proposed for the 
pathogenesis of AESD based on an increase in glutamate/glutamine complex demonstrated by 
magnetic resonance spectroscopy [6]. Theophylline, which inhibits pyridoxal kinase (PDXK) 
[7], is associated with AESD [8]. PDXK activates vitamin B6 (VB6), which is required for the 
biosynthesis of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter [9] (Figure 
1). There is a case series report in which the use of VB6 might have prevented the worsening 
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of AESD [10]. Another report suggested that early administration of vitamins B1, B6, and L-
carnitine prevented the development of AESD [11]. Based on these reports, we hypothesized 
that VB6 may play a role in the pathogenesis of AESD, namely, VB6 deficiency in the brain 
may be an aggravating or triggering factor for AESD by downregulating the inhibitory 
system. To investigate this hypothesis, we conducted a study to measure VB6 compounds in 




Subjects consisted of pediatric (<18 years old) patients with AESD after early seizures and 
those with FS who were admitted to Okayama University Hospital or other hospitals in Japan 
that were participating in this study, and who underwent lumbar puncture for diagnostic 
purposes. The diagnostic criteria of AESD in this study were 1) seizure onset at the beginning 
of presumptive infection, especially with status epilepticus (early seizure) and either 2) 
seizure(s) 3 to 7 days after seizure onset (late seizure) or 3) restricted diffusion involving the 
subcortical white matter and/or cortex (bright tree appearance) by MRI 3 to 14 days after 
seizure onset. Patients receiving vitamin B6 therapy were excluded. The collected CSF 
samples were aliquoted and used for routine laboratory tests (e.g., cell count, protein, and 
glucose), cultures, and polymerase-chain reaction tests to determine causative organisms. The 
remaining CSF samples were protected from light and frozen below –70°C within 1 h for this 
study. Samples collected outside Okayama University Hospital were shipped on dry ice to our 
laboratory. 
 
This study was performed in accordance with the Declaration of Helsinki and approved by the 
Research Ethics Board at Okayama University Hospital. Written informed consent was 
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obtained from patients’ parents or guardians. 
 
2.2. Vitamin B6 assay 
We measured the CSF concentrations of pyridoxal 5′-phosphate (PLP) and pyridoxal (PL) 
using the previously reported method [12]. In brief, 100 µL of CSF samples were derivatized 
by semicarbazide hydrochloride. Thereafter, PLP and PL were separated and their 
concentrations were determined by high-performance liquid chromatography with 
fluorescence detection. 
 
2.3. Statistical analysis 
Statistical analysis was conducted by R 3.4.2 (https://cran.r-project.org/). Group comparison 
was performed by Wilcoxon’s rank sum test. The significance level was set at 0.05. 
 
3. Results 
3.1. Subject characteristics 
There were 5 patients with AESD and 17 patients with FS. Most FS patients had complex FS, 
that is, prolonged and/or clustering seizures. The age of onset was 2 months to 5 years 2 
months (median, 1 year 0 months) in AESD and 8 months to 4 years 11 months (median, 1 
year 5 months) in FS, and there were no significant differences between AESD and FS (p = 
0.271). The timing of CSF sample collection was 0 to 1 day (median, 0 days) in AESD and 0 
to 2 days (median, 0 days) in FS after seizure onset, which were not significantly different (p 
= 1.0). Clinical characteristics are presented in Table 1. 
 
3.2. Vitamin B6 assay 
PLP and PL concentrations and PLP-to-PL ratios (PLP/PL) are presented in Figure 2. Most 
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patients with FS had PLP and PL concentrations and PLP-to-PL ratios within the reference 
range. Three out of five (60%) patients with AESD had low PLP concentrations, and four out 
of five (80%) patients had PLP-to-PL ratios that were low or around the lower limit of the 
reference range. One patient with AESD had a PLP concentration (54.9 nmol/L) and a PLP-
to-PL ratio (1.3) that slightly exceeded the upper limit of the reference range. The CSF PLP 
concentration was <3.5 (below the low limit of quantitation) to 54.9 nmol/L (median 11.3 
nmol/L) and 16.2 to 53.7 nmol/L (31.5 nmol/L) in AESD and FS, respectively. The CSF PLP 
concentration in AESD tended to be lower than that in FS (p = 0.0999). The PL concentration 
was 22.0 to 42.4 nmol/L (30.0 nmol/L) and 11.5 to 58.5 nmol/L (28.5 nmol/L) in AESD and 
FS, respectively. There was no significant difference in CSF PL concentration between AESD 
and FS (p = 1.0). The PLP-to-PL ratio was 0.1 to 1.3 (0.5) and 0.5 to 2.5 (1.0) in AESD and 
FS, respectively. The PLP-to-PL ratio in AESD was significantly lower than that in FS (p = 
0.0417). There were no significant differences in CSF PLP concentration (p = 0.778) and 
PLP-to-PL ratio (p = 0.438) between patients with known causative organisms and patients 
with unknown etiologies. 
 
4. Discussion 
The analysis of CSF VB6 demonstrated marginally lower PLP concentration and significantly 
lower PLP-to-PL ratio in AESD compared with FS. Although we cannot conclude that 
reduced PLP is the cause of AESD, we speculate that low CSF PLP may be a risk factor for 
developing AESD. Whether PLP reduction occurred acutely at the onset of AESD or baseline 
PLP concentration was low before AESD onset is unclear. There was one patient with AESD 
who had a CSF PLP concentration and a PLP-to-PL ratio that were slightly higher than the 
upper limit of the reference range. This suggests that there are factors other than PLP 
contributing to the development of AESD in this patient. 
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Because PLP cannot cross the blood–brain and blood–CSF barriers directly, PLP in the CSF is 
mainly produced within the choroid plexus, where PL is taken up from plasma and converted 
to PLP by intracellular PDXK [13] (Figure 1). Therefore, the reduced PLP-to-PL ratio in the 
CSF may reflect reduced PDXK activity within the choroid plexus epithelial cells. Low PLP-
to-PL ratios in the serum and CSF have been reported in poisoning by gingkotoxin, a PDXK 
inhibitor [14]. Another possibility is increased activity of tissue-nonspecific alkaline 
phosphatase (TNSALP) expressed at the membrane of ependymal cells, which converts PLP 
to PL so that CSF PLP can be taken up into brain parenchyma (Figure 1). There is a genome-
wide association study that suggested a common single nucleotide polymorphism of the ALPL 
gene coding TNSALP affected the PLP-to-PL ratio in plasma and CSF [15]. 
 
Inflammation may also play a role in the reduced PLP-to-PL ratio in AESD. Decreased 
plasma PLP has been reported in inflammation, and alteration in PLP distribution reflecting 
the tissue-specific mobilization of PLP to the sites of inflammation is hypothesized [16]. In 
addition, PLP has recently been suggested as a scavenger of reactive oxygen species [16]. 
Whether similar phenomenon is happening in the brain with AESD is an open question. 
 
It is uncertain whether low CSF PLP is a surrogate marker of low PLP in the brain. Although 
there is no direct way to estimate intracellular PLP status in the brain, an investigation of 
functional VB6 biomarkers in the CSF may be worthwhile. For example, CSF 3-O-
methyldopa and 5-hydroxytriptophan become elevated when PLP is deficient in the brain, 
because of the reduced activity of PLP-dependent aromatic L-amino acid decarboxylase [17]. 
 
This study is significantly limited by its very small sample size. It was difficult to control the 
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condition of CSF collection in the emergency setting, although we tried to standardize sample 
handling protocol after collection. Future directions include confirmation by studies with 
larger sample size, functional VB6 biomarker assays in the CSF using targeted metabolome 
analysis, and investigation of factors affecting PDXK and TNSALP activity, such as 
polymorphisms of the PDXK and ALPL genes. 
 
5. Conclusion 
AESD patients after early seizures had marginally lower CSF PLP concentration and 
significantly reduced CSF PLP-to-PL ratio than in FS patients. Although this mechanism is 
uncertain, these findings may be useful to distinguish AESD from FS upon initial 
presentation, when combined with other markers. The therapeutic effect of VB6 for AESD 
remains to be elucidated. 
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Figure 1 
Transport and metabolism of PLP and PL 
GABA, gamma-aminobutyric acid; GAD, glutamate decarboxylase; PDXK, pyridoxal kinase; 
PL, pyridoxal; PLP, pyridoxal 5′-phosphate; TNSALP, tissue-nonspecific alkaline phosphatase 
 
Figure 2 
Results of PLP and PL assays in AESD and FS 
Panels A, B, and C: PLP and PL concentrations and PLP-to-PL ratios vs. age. Dashed lines 
indicate the upper and lower limits of our reference values [12]. Panels D, E, and F: PLP and 
PL concentrations and PLP-to-PL ratios in AESD and FS. Solid lines indicate median values. 
AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; FS, febrile 
seizure; PL, pyridoxal; PLP, pyridoxal 5′-phosphate 
 
 





Group Age Sex Causative 
organism 












   
1 AESD 5y 2m F Unknown >1 h 0 32 <1 184 BTA  4 
2 AESD 1y 0m F E. coli >24 h (cluster) 1 23 1 63 N  2 
3 AESD 0y 2m M Unknown Cluster 0 53 3 63 BTA  1 
4 AESD 0y 11m F Influenza A 44 min 0 22 <1 93 BTA  3 
5 AESD 1y 3m F HHV-6 Cluster 0 22 1 133 BTA  1 
6 FS 1y 10m F Unknown 40 min 0 9 <1 82  N 1 
7 FS 1y 5m M Unknown 35 min 0 15 1 142  N 1 
8 FS 1y 3m F Unknown 15 min 0 13 <1 88  N 1 
9 FS 4y 11m F Unknown 2 h (cluster) 0 19 <1 97  N 1 
10 FS 0y 9m F HHV-6 10 min 0 17 <1 99  N 1 
11 FS 1y 7m M Adenovirus 5 min 2 16 <1 68 N  1 
12 FS 1y 0m F HHV-6 25 min 0 18 <1 95 N  1 
13 FS 1y 4m M Unknown >3h (cluster) 0 9 1 84  N 1 
14 FS 0y 8m F Unknown Cluster 0 33 1 144 N  1 
15 FS 2y 3m F Unknown 26 min (cluster) 1 13 <1 126 N  1 
16 FS 1y 11m F Unknown 8 min 0 16 1 69   1 
17 FS 1y 0m F Unknown Cluster 0 12 3 84   1 
18 FS 1y 11m F Unknown Cluster 0 19 1 73   1 
19 FS 1y 6m F Unknown 45 min 1 12 5 72 N  1 
20 FS 1y 11m M Influenza A 14 min 0 16 <1 97  N 1 
21 FS 1y 0m M Unknown 1.5 h 0 23 <1 90 N  1 
22 FS 1y 5m M Unknown 1.5 h (cluster) 0 24 2 82 N  1 
 
AESD, acute encephalopathy with biphasic seizures and late reduced diffusion; BTA, bright tree appearance; CSF, cerebrospinal fluid; CT, 
computed tomography; FS, febrile seizure; MRI, magnetic resonance imaging; N, normal; PCPC, pediatric cerebral performance category 
